WE NEED TO EDUCATE THE SOCIETY ON GENETIC MODIFICATION TECHNOLOGY
There is a growing debate
about the potential value of modern biotechnology, and in particular of
genetically modified organisms in helping to achieve benefits and opportunities
envisioned in food security, health, alternative sources of energy, safe
environment and industrial grow. The challenge facing policy makers is not only
to understand what genetically modification (GM) technology can do but also to
establish the threats this technology presents. While, the potential of GM
technology is enormous, there are 3 critical issues: first, whether or not the
GM technologies offer sustainable food security option; second, what the
implications are for biosafety in human health and well-being; and third, the
extent of existing capacity to undertake research, effectively detect, monitor
and evaluate GM products and their use. The challenge for policy makers is how
to respond to the uncertainty about relative opportunities and genuine concerns
on perceived threats posed by GM technologies.
Biotechnology has been in existence for
decades. The technology uses principles and techniques that have been practiced
for thousands of years such as production of beer, wine, bread, yoghurt and
cheese. Traditional animal and plant breeding techniques are also a form of
pre-industrial biotechnology. The modern biotechnology becomes special since it
makes the above processes faster and more precise. Researchers can take a
single gene from a plant or animal cell and insert it into another plant or
animal cell of a different species (commonly known as transgenic). In the
natural settings this will take several years to happen through mutations and
is what is known as evolution. Modern biotechnology therefore brings changes
that occur slowlyduring evolution in traditional selective breeding to a faster
and more specific way. New species of
plants and animals are produced by natural modification during reproduction and
accumuleover many generations.
In compliance with the
International Conventions and Treaties, Kenya has also set a firm legal systems
and frameworks to safeguard her biodiversity and safety of her people and
environment as modern biotechnology research and development progresses in the
Country. The evidence is by the
enactment of Biosafety Bill into law in 2009; Establishment of the National
Biosafety Authority to regulate activities of GMOs in 2010; Appointment of the
NBA Board, 2010 for oversight on safe research and application of modern
biotechnology in Kenya and Development and gazettment of Biosafety regulations
on contained use, environmental release, Import, export and transit and labelling
in 2012. It is important to state that research on GMOs in Kenya operate under
these regulations and indeed the Kenyan researchers not only adhere to the
international laws to which Kenya is signatory but also observe Kenyan
regulations concerning the research, use and importation of GMO products.
Modified
living organisms result in products such as drugs, vaccines, food and feeds.
Modern Biotechnology techniques and products applicable in the health sector
that may be of value in developing countries include, molecular diagnostics,
recombinant vaccines, vaccine and drug delivery techniques, sequencing
pathogens, genomes, microbicides, bioinformatics, recombinant therapeutic
proteins and combinatorial chemistry. Other areas of modern
biotechnology that do not necessarily involve genetic engineering include the
use of enzymes and bacteria in a wide range of applications, such as: waste
management, industrial production, food production, remediation of contaminated
land. The underlying principle of the
production and use of genetically modified organism (GMO) products is in the
safety of their users be they human or animals. For this reason both laboratory
and field testing during development are highly controlled and subjected to
required regulatory rigors under both international and national laws.
Kenya has invested in research and development in
modern Biotechnology. For example KARI and KEMRI have projects in modern biotechnology
producing products and delivery of services. The Centre for Biotechnology Research and
Development (CBRD) of KEMRI include 5 research laboratories, all equipped and mandated to undertake basic and
biotechnology-related research on human diseases in Kenya, with the overall
goal to contribute in the improvement of human health and welfare.
Globally
many GM crops have been commercialized in more than 29 countries with a total
acreage of 395 million by 2011. These include, Maize, Soybean, Cotton, potato,
Canola, Tomato, Beetroots, Papaya, Squash, Rice, alfalfa. The traits that have
been included in most of these crops are mainly pest disease or herbicide
resistance, and nutritional enrichment (Biofortication). Kenya has not yet
commercialized any GM crop but have several crops at various stages of
development by KARI in collaboration with local and International partners.
Some of the crops include: Bt cotton to be commercialized in 2014; Drought
tolerant maize (Water efficient Maize for Africa-WEMA) under confined field trial (CFT) at KARI
Kiboko; Virus resistant Cassava at KARI Alupe and Mtwapa field stations,
Cassava enhanced with protein, Vit A, Zinc and Iron under trials (CFT) in KARI
Alupe, Sorghum with enhanced protein, Vit A, Zinc and Iron at KARI Kiboko
under trials (CFT) , Nitrogen Efficient
Maize (IMAS) whose confined field trials
are targeted to start in 2013. In
livestock sector, ILRI in Collaboration with KARI are studying possibilities of
producing a cow with tolerance to
trypanosomiasis; Recombinant viral vaccine for Rift valley fever, Lumpy skin
disease, in cattle, Sheep and Goat and is targeted for trials in 2013.
Application of
biotechnology on human health is accepted the world over as source for cheap but
safe generic drugs. The principle for drugs production remain basically the
same even with food crops involving rigorous laboratory testing and stringent
laboratory and field safety studies before regulatory authorities can allow
their use in both humans and animals. There are a number of drugs based on
monoclonal antibodies for treating various diseases such as rituximab for
B-cell lymphomas, trasfuzumab (for Her-2 positive breast cancer) which are
produced by GM technology. Vaccines include Hepatitis B, new a cellular
pertussis, pneumococcal, meningococcal, staphylococcal vaccine and Recombinant
DNA vaccine for HIV (trials). Hormones include insulin for management of
diabetes, tamoxifen for estrogen receptor positive breast cancer, Follicle
Stimulating Hormone (FSH) for management of infertility in women, growth
hormones in meat production (Livestock and fish).
The
recent reports linking GMOs to Cancer in the rat model has attracted a lot of
critique globally and is alarmist to say the least. Kenya has not yet commercialized
any GMO crops, but that notwithstanding, countries that commercialized the GMO
crops over 20 years ago do not have high cancer prevalence as is being reported
in the country. Currently, Cancer is estimated to be the third leading cause of
death in Kenya, after infectious diseases and cardiovascular diseases it is unlikely
that this has any association use of GMO products. In many cases, these cancer
have been associated with the rapidly changing lifestyle that our people have
adopted, the high infectious agents that predispose the population to high risk
human papilloma and HIV viruses, high malnutrition among many maladies. Given
that Kenya is largely a grain deficient nation, safe application of modern
biotechnology in food production should not be scuttled on the altar of
un-informed public opinion but should be based on sober and structured
research-based discussions. Otherwise the country risk of jeopardizing
research, conflict and drought relief as well as benefits that accrues from GMO
technology including drought tolerance and bio-fortification among others.It is important therefore to assure Kenyans that just
like most generic drugs are safe, most agricultural products developed
following the laid down due processes and in observation of the internationally
accepted human biosafety regulations are also safe for their use. In my opinion
more public awareness id required and society must be educated on these
sciences to make a decision on what to consume. Above all we must demistify
such sciences, but must not be afraid to embrace it tackle food insecurity.